Meckbach, Diana, Keim, Ulrike, Richter, Sabina, Leiter, Ulrike, Eigentler, Thomas K., Bauer, Jürgen, Pflugfelder, Annette, Büttner, Petra, Garbe, Claus, and Weide, Benjamin (2014) BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy. PLoS ONE, 9 (2). e89218. pp. 1-7.

Preview

PDF (Published Version) - Published Version Available under License Creative Commons Attribution. Download (375kB) | Preview

 

21

1061

Abstract

Background

The impact of BRAF tumor mutations on the natural course of disease of melanoma patients is controversial.

Patients and Methods

We analyzed the mutational status and overall survival of 215 patients receiving treatment with dacarbazine or temozolomide. All patients who started first-line treatment at our institution between 2000 and 2010 were included to prevent selection and bias due to thereafter arising therapeutic options.

Results

No patient received BRAF- or MEK-inhibitors during follow-up. Survival was associated with the pattern of visceral involvement, the presence of brain metastases and the serum lactate dehydrogenase level (all p<0.001). The BRAF-V600 mutational status was not associated with survival and no differences in overall survival were detected according to age, gender or to the cytotoxic agent used for therapy. In Cox regression analysis the presence of brain metastases (hazard ratio 2.3; p<0.001) and an elevated serum LDH (hazard ratio 2.5; p<0.001) were the only factors, which independently predicted survival.

Conclusions

No differences in prognosis were observed according to the BRAF mutational status in patients with distant metastasis treated with monochemotherapy.

Actions (Repository Staff Only)

Item Control Page